Insights into prion strains and neurotoxicity

Nature Reviews Molecular Cell Biology

Volumn 8, Issue 7, 2007, Pages 552-561

  Aguzzi, Adriano ^a   Heikenwalder, Mathias ^a   Polymenidou, Magdalini ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN;

CENTRAL NERVOUS SYSTEM; CHRONIC WASTING DISEASE; CREUTZFELDT JAKOB DISEASE; DISEASE SEVERITY; FATAL FAMILIAL INSOMNIA; GENOMICS; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; GLYCOSYLATION; HUMAN; INOCULATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRION DISEASE; PRIORITY JOURNAL; PUBLIC HEALTH; RETICULOENDOTHELIAL SYSTEM; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BRAIN; CONSERVED SEQUENCE; CREUTZFELDT-JAKOB SYNDROME; DISEASE TRANSMISSION, HORIZONTAL; FORECASTING; GLYCOSYLATION; HUMANS; INCIDENCE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PRION DISEASES; PRIONS; PROTEIN SORTING SIGNALS; PROTEIN STRUCTURE, SECONDARY; PRPSC PROTEINS; SCRAPIE; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; VARIATION (GENETICS);

ANIMALIA;

EID: 34250796761     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm2204     Document Type: Review

References (137)

1. Glatzel, M. et al. Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurol. 2, 757-763 (2003).
2. Collins, P. S., Lawson, V. A. & Masters, P. C. Transmissible spongiform encephalopathies. Lancet 363, 51-61 (2004).
3. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982). Enunciation of the 'protein-only' hypothesis and definition of the prion.
4. Griffith, J. S. Self-replication and scrapie. Nature 215, 1043-1044 (1967). First communication of the 'protein-only' hypothesis.
5. Aguzzi, A. & Heikenwalder, M. Prion diseases: cannibals and garbage piles. Nature 423, 127-129 (2003).
6. Oesch, B., Groth, D. F., Prusiner, S. B. & Weissmann, C. Search for a scrapie-specific nucleic acid: a progress report. Ciba Found. Symp. 135, 209-223 (1988).
7. Oesch, B. et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-746 (1985).
8. Prusiner, S. B. Creutzfeldt-Jakob disease and scrapie prions. Alzheimer Dis. Assoc. Disord. 3, 52-78 (1989).
9. Weissmann, C. A 'unified theory' of prion propagation. Nature 352, 679-683 (1991).
10. 0/0 mice are resistant to prion disease.
11. Aguzzi, A. & Polymenidou, M. Mammalian prion biology. One century of evolving concepts. Cell 116, 313-327 (2004).
12. Zhang, C. C., Steele, A. D., Lindquist, S. & Lodish, H. F. Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc. Natl Acad. Sci. USA 103, 2184-2189 (2006).
13. c) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc. Natl Acad. Sci. USA 103, 3416-3421 (2006).
14. Silveira, J. R. et al. The most infectious prion protein particles. Nature 437, 257-261 (2005).
15. Telling, G. C. et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83, 79-90 (1995).
16. Priola, S. A., Chesebro, B. & Caughey, B. Biomedicine. A view from the top - prion diseases from 10,000 feet. Science 300, 917-919 (2003).
17. Bolton, D. C., McKinley, M. P. & Prusiner, S. B. Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311 (1982).
18. Safar, J. G. et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nature Biotech. 20, 1147-1150 (2002).
19. Sigurdson, C. J. et al. Strain fidelity of chronic wasting disease upon murine adaptation. J. Virol. 80, 12303-12311 (2006).
20. Richt, J. A. et al. Characterization of the recent U.S. BSE case and methods for surveillance. Proc. Annu. Meet. US Anim. Health Assoc. 108, 91-92 (2004).
21. Heikenwalder, M. et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 307, 1107-1110 (2005). Inflammatory conditions support prion replication in otherwise prion-free organs.
22. Seeger, H. et al. Coincident scrapie infection and nephritis lead to urinary prion excretion. Science 310, 324-326 (2005).
23. Sc in mammary glands of sheep affected by scrapie and mastitis. Nature Med. 11, 1137-1138 (2005).
24. Houston, F., Foster, J. D., Chong, A., Hunter, N. & Bostock, C. J. Transmission of BSE by blood transfusion in sheep. Lancet 356, 999-1000 (2000).
25. Mathiason, C. K. et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314, 133-136 (2006).
26. Llewelyn, C. A. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417-421 (2004).
27. Peden, A. H., Head, M. W., Ritchie, D. L., Bell, J. E. & Ironside, J. W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527-529 (2004). A case report of accidental CJD transmission through blood transfusion.
28. Wroe, S. J. et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368, 2061-2067 (2006).
29. Aguzzi, A. & Glatzel, M. Prion infections, blood and transfusions. Nature Clin. Pract. Neurol. 2, 321-329 (2006).
30. Sc molecules with different conformations. Nature Med. 4, 1157-1165 (1998).
31. Nonno, R. et al. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog. 2, e12 (2006).
32. Shorter, J. & Lindquist, S. Prions as adaptive conduits of memory and inheritance. Nature Rev. Genet. 6, 435-450 (2005).
33. Wickner, R. B., Edskes, H. K., Roberts, B. T., Pierce, M. & Baxa, U. Prions of yeast as epigenetic phenomena: high protein 'copy number' inducing protein 'silencing'. Adv. Genet. 46, 485-525 (2002).
34. Aguzzi, A. Understanding the diversity of prions. Nature Cell Biol. 6, 290-292 (2004).
35. Pattison, I. H. & Millson, G. C. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J. Comp. Pathol. 71, 101-108 (1961).
36. Fraser, H. & Dickinson, A. G. Scrapie in mice. Agentstrain differences in the distribution and intensity of grey matter vacuolation. J. Comp. Pathol. 83, 29-40 (1973).
37. Bruce, M. E. & Dickinson, A. G. Biological evidence that scrapie agent has an independent genome. J. Gen. Virol. 68, 79-89 (1987).
38. Kimberlin, R. H., Cole, S. & Walker, C. A. Temporary and permanent modifications to a single strain of mouse scrapie on transmission to rats and hamsters. J. Gen. Virol. 68, 1875-1881 (1987).
39. Race, R. et al. Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation of infectivity during four passages. J. Infect. Dis. 186 (Suppl. 2), S166-S170 (2002).
40. Hill, A. F. & Collinge, J. Subclinical prion infection in humans and animals. Br. Med. Bull. 66, 161-170 (2003).
41. Hill, A. F. et al. Species-barrier-independent prion replication in apparently resistant species. Proc. Natl Acad. Sci. USA 29, 10248-10253 (2000).
42. Collinge, J. et al. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378, 779-783 (1995).
43. Scott, M. R. et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl Acad. Sci. USA 96, 15137-151342 (1999).
44. Scott, M. R., Peretz, D., Nguyen, H. O., Dearmond, S. J. & Prusiner, S. B. Transmission barriers for bovine, ovine, and human prions in transgenic mice. J. Virol. 79, 5259-5271 (2005).
45. Scott, M. et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59, 847-857 (1989).
46. Vilotte, J. L. et al. Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine PrP. J. Virol. 75, 5977-5984 (2001).
47. Collinge, J., Sidle, K. C., Meads, J., Ironside, J. & Hill, A. F. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 383, 685-690 (1996).
48. Collinge, J. Molecular neurology of prion disease. J. Neurol. Neurosurg. Psychiatr. 76, 906-919 (2005).
49. Sc. J. Gen. Virol. 86, 2635-2644 (2005).
50. DeArmond, S. J. et al. Selective neuronal targeting in prion disease. Neuron 19, 1337-1348 (1997).
51. Neuendorf, E. et al. Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections. J. Biol. Chem. 279, 53306-53316 (2004).
52. Cancellotti, E. et al. Altered glycosylated PrP proteins can have different neuronal trafficking in brain but do not acquire scrapie-like properties. J. Biol. Chem. 280, 42909-42918 (2005).
53. Bessen, R. A. & Marsh, R. F. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68, 7859-7868 (1994). Describes the differentiation of prion strains by proteolytic digest.
54. Bessen, R. A. et al. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375, 698-700 (1995).
55. Telling, G. C. et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274, 2079-2082 (1996).
56. Parchi, P. et al. Genetic influence on the structural variations of the abnormal prion protein. Proc. Natl Acad. Sci. USA 97, 10168-10172 (2000).
57. Zanusso, G. et al. Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J. Biol. Chem. 279, 38936-38942 (2004).
58. Bruce, M. E. et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389, 498-501 (1997).
59. Palmer, M. S., Dryden, A. J., Hughes, J. T. & Collinge, J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340-342 (1991).
60. Collinge, J., Palmer, M. S. & Dryden, A. J. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337, 1441-1442 (1991).
61. Sc in the same brain. Neurology 53, 2173-2176 (1999).
62. Dickson, D. W. & Brown, P. Multiple prion types in the same brain: is a molecular diagnosis of CJD possible?. Neurology 53, 1903-1904 (1999).
63. Sc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol. 4, 805-814 (2005).
64. Yull, H. M. et al. Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Am. J. Pathol. 168, 151-157 (2006).
65. Nishida, N., Katamine, S. & Manuelidis, L. Reciprocal interference between specific CJD and scrapie agents in neural cell cultures. Science 310, 493-496 (2005).
66. Sc levels. J. Virol. 81, 689-697 (2007).
67. Dickinson, A. G., Fraser, H., Meikle, V. M. & Outram, G. W. Competition between different scrapie agents in mice. Nature New Biol. 237, 244-245 (1972).
68. Manuelidis, L. Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc. Natl Acad. Sci. USA 95, 2520-2525 (1998).
69. Casalone, C. et al. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc. Natl Acad. Sci. USA 101, 3065-3070 (2004).
70. Beringue, V. et al. Isolation from cattle of a prion strain distinct from that causing bovine spongiform encephalopathy. PLoS Pathog. 2, e112 (2006).
71. Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006).
72. Aguzzi, A. & Haass, C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302, 814-818 (2003).
73. Riek, R. Cell biology: infectious Alzheimer's disease? Nature 444, 429-431 (2006).
74. Aguzzi, A. & Sigurdson, C. J. Antiprion immunotherapy: to suppress or to stimulate? Nature Rev. Immunol. 4, 725-736 (2004).
75. Brown, P. et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol. 35, 513-529 (1994).
76. Glatzel, M., Abela, E., Maissen, M. & Aguzzi, A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 349, 1812-1820 (2003).
77. Sc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease. Am. J. Pathol. 168, 927-935 (2006).
78. Blättler, T. et al. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 389, 69-73 (1997).
79. Brown, K. L. et al. Scrapie replication in lymphoid tissues depends on prion protein- expressing follicular dendritic cells. Nature Med. 5, 1308-1312 (1999).
80. Bartz, J. C., Dejoia, C., Tucker, T., Kincaid, A. E. & Bessen, R. A. Extraneural prion neuroinvasion without lymphoreticular system infection. J. Virol. 79, 11858-11863 (2005).
81. Bessen, R. A. & Marsh, R. F. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J. Virol. 66, 2096-2101 (1992).
82. Telling, G. C. et al. Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc. Natl Acad. Sci. USA 91, 9936-9940 (1994).
83. Büeler, H. R. et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582 (1992).
84. Mallucci, G. R. et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21, 202-210 (2002).
85. Sc in vivo and antagonizes prion disease. Cell 113, 49-60 (2003).
86. Brandner, S. et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343 (1996).
87. C in prion-induced neurotoxicity.
88. Chesebro, B. et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308, 1435-1439 (2005).
89. Aguzzi, A. Cell biology. Prion toxicity: all sail and no anchor. Science 308, 1420-1421 (2005).
90. Kimberley, F. C., Sivasankar, B. & Paul Morgan, B. Alternative roles for CD59. Mol. Immunol. 44, 73-81 (2007).
91. Trifilo, M. J. et al. Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. Science 313, 94-97 (2006).
92. Shmerling, D. et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93, 203-214 (1998).
93. C. J. Neurosci. 25, 4879-4888 (2005).
94. Baumann, F. et al. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J. 26, 538-547 (2007).
95. Hegde, R. S. et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 279, 827-834 (1998).
96. Hegde, R. S. et al. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402, 822-826 (1999).
97. Stewart, R. S., Piccardo, P., Ghetti, B. & Harris, D. A. Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J. Neurosci. 25, 3469-3477 (2005).
98. Ma, J., Wollmann, R. & Lindquist, S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298, 1781-1785 (2002).
99. Sc-like conformation in the cytosol. Science 298, 1785-1788 (2002).
100. Drisaldi, B. et al. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J. Biol. Chem. 278, 21732-21743 (2003).
101. Roucou, X., Guo, Q., Zhang, Y., Goodyer, C. G. & LeBlanc, A. C. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278, 40877-40881 (2003).
102. Barmada, S., Piccardo, P., Yamaguchi, K., Ghetti, B. & Harris, D. A. GFP-tagged prion protein is correctly localized and functionally active in the brains of transgenic mice. Neurobiol. Dis. 16, 527-537 (2004).
103. Barmada, S. J. & Harris, D. A. Visualization of prion infection in transgenic mice expressing green fluorescent protein-tagged prion protein. J. Neurosci. 25, 5824-5832 (2005).
104. Ford, M. J., Burton, L. J., Morris, R. J. & Hall, S. M. Selective expression of prion protein in peripheral tissues of the adult mouse. Neuroscience 113, 177-192 (2002).
105. Herms, J. et al. Evidence of presynaptic location and function of the prion protein. J. Neurosci. 19, 8866-8875 (1999).
106. Moser, M., Colello, R. J., Pott, U. & Oesch, B. Developmental expression of the prion protein gene in glial cells. Neuron 14, 509-517 (1995).
107. Stahl, N., Borchelt, D. R., Hsiao, K. & Prusiner, S. B. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51, 229-240 (1987).
108. Haraguchi, T. et al. Asparagine-linked glycosylation of the scrapie and cellular prion proteins. Arch. Biochem. Biophys. 274, 1-13 (1989).
109. Riek, R. et al. NMR structure of the mouse prion protein domain PrP (121-321). Nature 382, 180-182 (1996).
110. Wuthrich, K. & Riek, R. Three-dimensional structures of prion proteins. Adv. Protein Chem. 57, 55-82 (2001).
111. Knaus, K. J. et al. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nature Struct. Biol. 8, 770-774 (2001).
112. Hornemann, S. et al. Recombinant full-length murine prion protein, mPrP (23-231): purification and spectroscopic characterization. FEBS Lett. 413, 277-281 (1997).
113. Brown, D. R. et al. The cellular prion protein binds copper in vivo. Nature 390, 684-687 (1997).
114. Garnett, A. P. & Viles, J. H. Copper binding to the octarepeats of the prion protein. Affinity, specificity, folding, and cooperativity: insights from circular dichroism. J. Biol. Chem. 278, 6795-6802 (2003).
115. 2+ ions at physiological concentrations. J. Mol. Biol. 346, 1393-1407 (2005).
116. Brown, D. R., Schulz-Schaeffer, W. J., Schmidt, B. & Kretzschmar, H. A. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 146, 104-112 (1997).
117. Waggoner, D. J. et al. Brain copper content and cuproenzyme activity do not vary with prion protein expression level. J. Biol. Chem. 275, 7455-7458 (2000).
118. Hutter, G., Heppner, F. L. & Aguzzi, A. No superoxide dismutase activity of cellular prion protein in vivo. Biol. Chem. 384, 1279-1285 (2003).
119. Enari, M., Flechsig, E. & Weissmann, C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA 98, 9295-9299 (2001).
120. Peretz, D. et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001).
121. Heppner, F. L. et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178-182 (2001).
122. White, A. R. et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83 (2003).
123. Koller, M. F., Grau, T. & Christen, P. Induction of antibodies against murine full-length prion protein in wild-type mice. J. Neuroimmunol. 132, 113-116 (2002).
124. Sigurdsson, E. M. et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17 (2002).
125. Sigurdsson, E. M. et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336, 185-187 (2003).
126. Tal, Y. et al. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. 71, 286-290 (2003).
127. Souan, L., Margalit, R., Brenner, O., Cohen, I. R. & Mor, F. Self prion protein peptides are immunogenic in Lewis rats. J. Autoimmun. 17, 303-310 (2001).
128. Souan, L. et al. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31, 2338-2346 (2001).
129. Schwarz, A. et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350, 187-189 (2003).
130. Arbel, M., Lavie, V. & Solomon, B. Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J. Neuroimmunol. 144, 38-45 (2003).
131. Gregoire, S. et al. Identification of two immunogenic domains of the prion protein - PrP - which activate class II-restricted T cells and elicit antibody responses against the native molecule. J. Leukoc. Biol. 76, 125-134 (2004).
132. Rosset, M. B. et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J. Immunol. 172, 5168-5174 (2004).
133. Polymenidou, M. et al. Humoral immune response to native eukaryotic prion protein correlates with antiprion protection. Proc. Natl Acad. Sci. USA 101, 14670-14676 (2004).
134. Lechner, F. et al. Virus-like particles as a modular system for novel vaccines. Intervirology 45, 212-217 (2002).
135. Nikles, D. et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J. Virol. 79, 4033-4042 (2005).
136. Solforosi, L. et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303,1514-1516 (2004).
137. Nicoll, J. A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med. 9, 448-452 (2003).